Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12972960 | 0.75 | ALDH1A1 (0.44) | ALDH1A1HSD17B10HPGDMEN1MAPT | |
| SCHEMBL12607739 | 0.71 | ALDH1A1 (0.30) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12607754 | 0.71 | ALDH1A1 (0.30) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14877786 | 0.71 | ALDH1A1 (0.30) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL19101171 | 0.68 | NPC1 (0.41) | ALDH1A1HSD17B10HPGDMEN1MAPT | |
| SCHEMBL17149564 | 0.68 | NPC1 (0.41) | ALDH1A1HSD17B10HPGDMEN1MAPT | |
| SCHEMBL17151014 | 0.68 | NPC1 (0.41) | ALDH1A1HSD17B10HPGDMEN1MAPT | |
| SCHEMBL17996705 | 0.66 | MAPT (0.41) | ALDH1A1HSD17B10HPGDMEN1MAPT | |
| SCHEMBL12607740 | 0.66 | GPR35 (0.33) | ALDH1A1HSD17B10HPGDMEN1MAPT | |
| SCHEMBL12607744 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3307742-B1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE INC (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022011091-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| EP-2911671-B1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | PSMG3, HSPA5, TTR | ALDH1A1 4128/4885HSD17B10 2968/4885HPGD 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.